Eli Lilly executives said there’s every reason to be optimistic about future sales of Effient, the blood thinner launched last summer with expectations of perhaps growing to become a billion-dollar seller one day. The only worry seems to be early sales of the drug are headed in the wrong direction. Reporting its fourth-quarter results , Lilly said that sales of Effient, which the company co-markets with Japan’s Daiichi Sankyo, slid to a tiny $3.8 million world-wide in the fourth quarter

Read more:
Lilly’s Effient: Slow Start for a New Blood Thinner

Share and Enjoy:
  • Print
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google Bookmarks

Tagged with: • • • • • • • • • • • •

Filed under: Drugs • ED • Eli Lilly • IT • Uncategorized • heal • health • patent

Like this post? Subscribe to my RSS feed and get loads more!